首頁 > 市場調查報告書 > 製藥

骨疾病

市場調查報告書

商品編碼

2058236

抗骨質疏鬆和骨折癒合市場：依藥物類別、給藥途徑、分銷管道和地區分類。

Anti-Osteoporosis And Fracture Healing Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年05月08日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年，抗骨質疏鬆和骨折癒合市場規模估計為185億美元，預計2033年將達到248億美元。預計從2026年到2033年，該市場將以11.3%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	185億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	11.30%	2033年市場規模預測：	248億美元

受全球人口老化、骨質疏鬆症盛行率上升以及全球脆性骨折發生率增加的推動，市場正經歷強勁成長。人們對骨骼健康的日益關注、骨骼密度檢測等診斷手段的普及以及治療方法的不斷增多，都進一步促進了市場擴張。

抗骨質疏鬆和骨折癒合療法在預防骨質流失、提高骨骼密度、降低骨折風險以及促進骨折後復原方面發揮著至關重要的作用。該市場涵蓋雙磷酸鹽、荷爾蒙補充療法、單株抗體、骨形成促進劑以及其他口服和注射先進療法。其中，雙磷酸鹽因其療效確切、價格合理且被廣泛用作骨質疏鬆症一線治療藥物，繼續佔據市場主導地位。

生物製藥、成骨療法和生物相似藥的技術進步正在改變治療方法並改善患者預後。此外，監管機構對創新治療方法的支持力度加大、醫療保健支出不斷成長以及醫院骨折管理項目的擴展，都在加速全球市場成長。Denosumab、羅莫索單抗和特立帕肽等先進治療方法的快速上市也加劇了市場競爭。

市場動態

受多種人口、臨床和醫療保健相關因素的影響，骨質疏鬆症和骨折癒合市場正經歷顯著成長。其中一個關鍵成長要素是全球骨質疏鬆症負擔日益加重。骨質疏鬆症影響全球約2億人，每年造成約890萬例骨折，因此對長期治療性介入和骨折管理解決方案的需求持續強勁。

另一個重要的成長要素是人口老化的快速發展。至2050年，全球約六分之一的人口將達到或超過65歲，預計骨質疏鬆症及相關骨折的風險族群數量將顯著增加。停經後婦女和老年人仍然是最易感人群，因此對預防和治療的需求持續成長。

此外，口服療法因其便利性、非侵入性給藥方式以及較高的患者依從性，正日益普及並進一步推動市場發展。研究表明，在慢性病管理中，60-70%甚至更多的患者更傾向於口服藥物而非注射藥物。此外，鑑於骨折相關住院人數眾多以及專科主導的骨質疏鬆症診療路徑的建立，醫院藥房在治療藥物供應方面發揮著至關重要的作用。

藥物研發領域的持續創新也是市場的主要驅動力。美國食品藥物管理局（FDA）等監管機構正透過快速通道和突破性療法認定，加速合成代謝療法和生物製藥的核准，從而支持下一代治療方法的快速上市。生物相似藥和先進單株抗體療法的推出也改善了已開發國家和新興國家患者獲得治療的機會。

然而，生物製藥治療成本高昂、用藥依從性差、監管市場的價格壓力等因素可能會在一定程度上限制市場成長。儘管患者用藥途徑有所改善，但中國基於採購量和積極的藥品價格談判等政策仍持續擠壓製藥公司的利潤空間。不過，醫療基礎設施的不斷改進、骨折預防意識的提高以及醫療支出的成長預計將支撐全球市場的長期擴張。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數對骨質疏鬆症和骨折癒合市場的主要參與者進行了分析：公司亮點、服務組合、關鍵發展、財務績效和策略。
透過利用本報告中的見解，行銷負責人和經營團隊將能夠就未來的服務創新、市場擴張和策略合作夥伴關係做出明智的決策。
《骨質疏鬆症和骨折癒合市場》報告的目標受群眾外包括投資者、服務供應商、製藥公司、監管機構和金融分析師等各類相關人員。
相關人員可以利用系統分析框架和策略矩陣來評估骨質疏鬆症和骨折癒合市場，從而獲得巨大利益。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
市佔率分析
公司簡介
- Radius Health Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- GlaxoSmithKline Plc.
- Merck & Co., Inc.
- F. Hoffman-La Roche AG
- Eli
- Lilly and Company Limited
- PhytoHealth Corporation

第9章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI2525

Anti-Osteoporosis And Fracture Healing Market is estimated to be valued at USD 18.5 Bn in 2026 and is expected to reach USD 24.8 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.3% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 18.5 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	11.30%	2033 Value Projection:	USD 24.8 Bn

The market is experiencing strong growth driven by the rapidly aging global population, increasing prevalence of osteoporosis, and rising incidence of fragility fractures worldwide. Growing awareness regarding bone health, improved diagnostic access through bone mineral density screening, and expanding treatment adoption are further supporting market expansion.

Anti-osteoporosis and fracture healing therapies play a critical role in preventing bone loss, improving bone density, reducing fracture risk, and supporting post-fracture recovery. The market includes bisphosphonates, hormone replacement therapies, monoclonal antibodies, anabolic agents, and other advanced therapeutics used across oral and injectable formulations. Among these, bisphosphonates continue to dominate due to their proven efficacy, affordability, and widespread use as first-line therapy for osteoporosis management.

Technological advancements in biologics, anabolic bone-forming therapies, and biosimilars are transforming treatment approaches and improving patient outcomes. In addition, increasing regulatory support for innovative therapies, rising healthcare expenditure, and the expansion of hospital-based fracture management programs are accelerating global market growth. Strong adoption of advanced therapies such as denosumab, romosozumab, and teriparatide is also strengthening the competitive landscape of the market.

Market Dynamics

The Anti-Osteoporosis And Fracture Healing Market is witnessing substantial growth due to multiple demographic, clinical, and healthcare-related factors. One of the primary growth drivers is the increasing burden of osteoporosis globally. Osteoporosis affects nearly 200 million people worldwide and contributes to approximately 8.9 million fractures annually, creating sustained demand for long-term therapeutic intervention and fracture management solutions.

Another significant growth factor is the rapidly expanding geriatric population. By 2050, approximately 1 in 6 people globally will be aged 65 years or older, significantly increasing the population at risk for osteoporosis and related fractures. Postmenopausal women and elderly individuals remain the most vulnerable patient groups, driving continuous demand for preventive and therapeutic treatments.

The market is further supported by strong adoption of oral therapies owing to their convenience, non-invasive administration, and better patient adherence. Studies indicate that more than 60-70% of patients prefer oral medications over injectable alternatives for chronic disease management. Hospital pharmacies also play a major role in treatment distribution due to the high volume of fracture-related hospitalizations and specialist-led osteoporosis care pathways.

Continuous innovation in drug development is another key market driver. Regulatory agencies such as the U.S. Food and Drug Administration are accelerating approvals for anabolic and biologic therapies through fast-track and breakthrough therapy designations, supporting faster commercialization of next-generation treatments. Biosimilar launches and advanced monoclonal antibody therapies are also improving treatment accessibility across developed and emerging economies.

However, factors such as high treatment costs for biologics, medication adherence challenges, and pricing pressures in regulated markets may limit market growth to some extent. Policies such as China's volume-based procurement and aggressive drug price negotiations continue to compress profit margins for pharmaceutical manufacturers despite improving patient access. Nevertheless, expanding healthcare infrastructure, rising awareness regarding fracture prevention, and increasing healthcare spending are expected to support long-term market expansion globally.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Anti-Osteoporosis And Fracture Healing Market based on the following parameters - company highlights, service portfolio, key developments, financial performance, and strategies
Key companies covered as a part of this study include Radius Health Inc., Pfizer Inc., Amgen Inc., Novartis AG, GlaxoSmithKline Plc., Merck & Co., Inc., F. Hoffman-La Roche AG, Eli, Lilly and Company Limited, and PhytoHealth Corporation
Insights from this report would allow marketers and management authorities to make informed decisions regarding future service innovations, market expansion, and strategic partnerships
The Anti-Osteoporosis And Fracture Healing Market report caters to various stakeholders including investors, service providers, pharmaceutical companies, regulatory bodies, and financial analysts
Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Anti-Osteoporosis And Fracture Healing Market

Market Segmentation

By Drug Class (Revenue, USD Bn, 2026-2033)
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic acid
- Hormone replacement therapy
- Estrogen
- Progestin
- Others
- Monoclonal Antibodies
- Denosumab
- Romosozumab
- Anabolic Agents
- Alendronate
- Teriparatide
- Others
By Route of Administration (Revenue, USD Bn, 2026-2033)
- Oral
- Injection
By Distribution Channel (Revenue, USD Bn, 2026-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region (Revenue, USD Bn, 2026-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Key Players
- Radius Health Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- GlaxoSmithKline Plc.
- Merck & Co., Inc.
- Hoffman-La Roche AG
- Eli, Lilly and Company Limited
- PhytoHealth Corporation

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Anti-Osteoporosis And Fracture Healing Market, By Drug Class, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Bisphosphonates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  - Alendronate
  - Risedronate
  - Ibandronate
  - Zoledronic acid
Hormone replacement therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  - Estrogen
  - Progestin
  - Others
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  - Denosumab
  - Romosozumab
Anabolic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  - Alendronate
  - Teriparatide
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Anti-Osteoporosis And Fracture Healing Market, By Route of Administration, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Anti-Osteoporosis And Fracture Healing Market, By Distribution Channel, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Global Anti-Osteoporosis And Fracture Healing Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Radius Health Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- GlaxoSmithKline Plc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- F. Hoffman-La Roche AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Eli
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Lilly and Company Limited
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- PhytoHealth Corporation
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
  - Analyst Views